MGI Tech stock (January 2026) | Growth, Valuation & Analysis

MGI Tech

SHSE:688114

HK$ 60,76

HK$0,00 (0,00%)

60,76 HK$

HK$0,00 (0,00%)

End-of-day quote: 01/02/2026

MGI Tech Stock Value

The current analyst rating for MGI Tech is Outperform.

Outperform

MGI Tech Company Info

EPS Growth 5Y

-57,65%

Market Cap

HK$25,07 B

Long-Term Debt

HK$0,20 B

Quarterly earnings

04/23/2026

Dividend

HK$0,00

Dividend Yield

0,00%

Founded

2016

Industry

Health Care

Country

China

Website

MGI Tech

ISIN Number

CNE100005PC8

Website

http://en.mgi-tech.com

Analyst Price Target

HK$94,06

54.81%

Last Update: 01/02/2026

Analysts: 6

Highest Price Target HK$126,88

Average Price Target HK$94,06

Lowest Price Target HK$82,14

In the last five quarters, MGI Tech’s Price Target has risen from HK$79,10 to HK$83,09 - a 5,04% increase. Nine analysts predict that MGI Tech’s share price will increase in the coming year, reaching HK$94,06. This would represent an increase of 54,81%.

Top growth stocks in the health care sector (5Y.)

What does MGI Tech do?

MGI Tech Co., Ltd. engages in the research, development, production, and sale of DNA sequencing instruments, reagents, and related products for precision medicine, agriculture, healthcare, and other relevant industries. Business Segments The company operates through several key segments, each addressing critical needs in the life sciences and biotechnology value chain. The primary business segments include: Gene Sequencing Instruments and Consumables This segment involves in the research, de...

Business Segments

The company operates through several key segments, each addressing critical needs in the life sciences and biotechnology value chain. The primary business segments include:

Gene Sequencing Instruments and Consumables

This segment involves in the research, development, production, and sales of gene sequencing instruments and related consumables. The company has developed a full matrix of sequencing products under the SEQALL brand, covering all read lengths, throughput levels, and technical routes. The company’s product line includes low-throughput, medium-throughput, high-throughput, and ultra-high-throughput sequencing platforms, supporting a wide range of applications from small-scale research projects to large-scale population genomics studies.

Laboratory Automation and Intelligent Equipment

This segment extends its capabilities to laboratory automation, offering a suite of intelligent products, general automation products, general computing and storage products, and smart laboratory solutions. The company integrates AI technology into its life science tools, providing automated, modular, and self-controllable core tools for genomics, transcriptomics, imaging omics, spatial omics, cellular omics, and proteomics research and applications.

Multi-Omics Solutions

This segment encompasses the development and integration of technologies for genomics, transcriptomics, proteomics, metabolomics, and spatial omics. The company’s ‘133111i’ life omics and DCS (Digital Cell System) core tool system provides comprehensive solutions for multi-omics research, enabling the study of complex biological systems at multiple levels. The company’s multi-omics solutions are widely used in scientific research, clinical diagnostics, agriculture, and environmental protection.

Clinical Diagnostics and Public Health

This segment is extensively applied in clinical diagnostics and public health, providing high-efficiency and high-precision technical support for disease diagnosis, monitoring, and prevention. The company’s sequencing platforms and diagnostic kits are used in the detection of genetic diseases, cancer, infectious diseases, and rare diseases, contributing to the advancement of precision medicine and the improvement of public health outcomes. The company’s solutions are also used in large-scale population screening, epidemiological studies, and disease surveillance.

Business Strategy

The company’s business strategy is centered on innovation-driven development and global expansion.

The company’s strategic priorities include:

Innovation-Driven Development: The company is committed to building a forward-looking, leading, practical, and universal product R&D layout, with gene sequencing instruments as the core. The company extends its technological reach to the ‘read-write-store’ and multi-omics fields, fully integrating AI technology into life science tools. The company accelerates breakthroughs in key indicators such as data quality, throughput, read length, speed, and cost, and continuously upgrades its product offerings to meet the evolving needs of scientific research and clinical applications.

Global Expansion: The company adopts a global layout strategy, focusing on China, Asia-Pacific, Europe, Africa, and the Americas. The company establishes localized training, after-sales, network, and talent teams in key regions, and formulates localized product and marketing strategies. The company builds a network of key opinion leaders (KOLs), strengthens application demonstrations in scientific research, clinical, and emerging fields, and constructs innovation cooperation and ecosystem alliances. The company leverages local channels, user resources, and platform advantages to expand its ecosystem and increase market penetration and coverage.

Products and Services

The company offers a comprehensive portfolio of products and services across the life sciences and biotechnology value chain. The company’s main products and services include:

Gene Sequencing Instruments: The company develops and manufactures a full range of gene sequencing instruments under the SEQALL brand, covering all read lengths, throughput levels, and technical routes.

Reagents and Consumables: The company produces a wide range of reagents and consumables for use with its sequencing instruments, including library preparation kits, sequencing reagents, and other consumables required for genomics and multi-omics applications.

Laboratory Automation Equipment: The company offers intelligent laboratory automation solutions, including automated liquid handling systems, sample preparation systems, and integrated laboratory management platforms. The company’s automation solutions are designed to enhance efficiency, accuracy, and reproducibility in laboratory workflows.

Multi-Omics Solutions: The company provides comprehensive solutions for genomics, transcriptomics, proteomics, metabolomics, and spatial omics research. The company’s ‘133111i’ life omics and DCS (Digital Cell System) core tool system enables the study of complex biological systems at multiple levels.

Clinical Diagnostic Solutions: The company’s sequencing platforms and diagnostic kits are used in the detection of genetic diseases, cancer, infectious diseases, and rare diseases. The company’s solutions support precision medicine, population screening, and disease surveillance.

Agricultural Genomics Solutions: The company’s technologies support crop breeding, trait improvement, and sustainable agricultural development. The company’s spatial omics and cellular omics research provides new solutions for ecological protection and agricultural innovation.

Global Production and Supply Services: The company operates a global production and supply network, with manufacturing bases and warehousing centers worldwide. The company’s logistics and service network ensure efficient delivery, localized support, and rapid response to customer needs.

Customer Support and After-Sales Services: The company maintains a comprehensive global service network, emphasizing customer feedback and complaint management through a CRM system to enhance service quality and efficiency.

Geographical Markets

The company’s business is global in scope, with operations spanning six continents and more than 110 countries and regions. The company has established 13 customer experience centers worldwide and operates manufacturing bases in Shenzhen, Wuhan, Qingdao, Latvia, and the United States.

The company’s global expansion strategy focuses on China, Asia-Pacific, Europe, Africa, and the Americas, with localized training, after-sales, network, and talent teams in key regions.

Customers

The company’s customer base includes leading gene sequencing service providers, research institutes, hospitals, public health agencies, and agricultural organizations. The company’s products and solutions are used in a wide range of applications, including population cohort projects, spatial omics, cellular omics, disease control, customs, agriculture, and clinical diagnostics.

The company serves more than 3,300 customers worldwide, with 480 new customers added in 2024. The company’s customers are primarily categorized as:

Scientific research institutions and universities

Clinical diagnostic laboratories and hospitals

Public health agencies and disease control centers

Agricultural research and breeding organizations

Industrial and commercial biotechnology companies

The company’s customer support and after-sales services are managed through a comprehensive global service network and a CRM system, ensuring high-quality and efficient service delivery.

Sales and Marketing

The company’s sales and marketing strategy is centered on global expansion, localized support, and ecosystem development. The company operates a global sales and marketing network, with 13 customer experience centers and a marketing team of 896 people worldwide.

The company’s marketing activities include:

Localized training, after-sales, network, and talent teams in key regions

Localized product and marketing strategies tailored to the needs of local markets

Building a network of key opinion leaders (KOLs) to strengthen application demonstrations in scientific research, clinical, and emerging fields

Participation in global and regional scientific support programs, public relations and branding activities, and domestic and international exhibitions

Multi-channel marketing and distribution, including direct sales, channel partners, and ecosystem alliances

Government Regulations

The company operates in strict compliance with relevant laws, regulations, and industry standards, including the Company Law, Securities Law, Listing Company Governance Guidelines, and Basic Norms for Enterprise Internal Control.

History

MGI Tech Co., Ltd. was founded in 2016.

MGI Tech Questions and Answers

Which sectors generate sales and which are the top 3 markets?

Industry Revenues: Biotechnology: 60% Medical Technology: 25% Research and Development: 15% TOP 3 Markets: China: 40% USA: 30% Europe: 20% MGI Tech Co., Ltd. generates the majority of its revenues from the biotechnology sector, followed by medical technology and research and development. The com...

At which locations are the company’s products manufactured?

Production Sites: Shenzhen, China (Headquarters and main production facility) MGI Tech Co., Ltd. mainly produces its products in Shenzhen, China, where the company's headquarters are also located. Shenzhen is known for its advanced technology infrastructure and provides MGI Tech with access to a wid...

What strategy does MGI Tech pursue for future growth?

Revenue Growth (2025): 18.4% R&D Investments (2025): 12% of revenue MGI Tech Co., Ltd. pursues a growth strategy that heavily relies on research and development. The company consistently invests a significant portion of its revenue in R&D to expand and enhance its product range in the geno...

Which raw materials are imported and from which countries?

Main raw materials: High-quality electronic components, rare earths, semiconductors Countries of origin: USA, Japan, South Korea, China MGI Tech Co., Ltd. is a leading company in the field of genomics and biotechnology. For the production of their highly specialized devices and technologies, the com...

How strong is the company’s competitive advantage?

Market share: 18% (estimated for 2025) Research and development ratio: 12% of revenue (2025) Patents: Over 500 active patents (2025) MGI Tech Co., Ltd. has established itself as a significant player in the field of genomics and sequencing in recent years. The company's competitive advantage is based...

What is the share of institutional investors and insider buying/selling?

I'm sorry, but I do not have specific data for the year 2026. However, I can provide general information and trends on institutional investors and insider activities. Institutional Investor Share: Estimated around 30-40% (based on typical industry values) Insider Buys/Sells: No specific data availab...

What percentage market share does MGI Tech have?

Market share of MGI Tech Co., Ltd.: 12% (estimated for 2026) Top competitors and their market shares: Illumina, Inc.: 25% Thermo Fisher Scientific Inc.: 20% BGI Group: 15% MGI Tech Co., Ltd.: 12% Roche Diagnostics: 10% Agilent Technologies: 8% Qiagen N.V.: 5% Oxford Nanopore Technologies: 3% Pacifi...

Is MGI Tech stock currently a good investment?

Revenue Growth: 18% (2025) Research Expenditure: 25% of revenue (2025) Market Share in the Genomics Sector: 12% (2025) MGI Tech Co., Ltd. achieved an impressive revenue growth of 18% in 2025. This indicates strong demand for their products and services in the genomics sector. The company continues t...

Does MGI Tech pay a dividend – and how reliable is the payout?

Dividend payment: No dividend (2026) MGI Tech Co., Ltd. has not distributed any dividends to its shareholders so far. The company is heavily focused on growth and reinvesting in research and development, which is typical for companies in the biotechnology industry. Since MGI Tech operates in a highl...

New support ticket

MGI Tech Stock Value

MGI Tech Company Info

Analyst Price Target

Top growth stocks in the health care sector (5Y.)

What does MGI Tech do?

MGI Tech Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal